Aveo Pharmaceuticals Inc., which failed to win the backing of U.S. regulatory advisers last month for its experimental kidney cancer drug, said it will cut about 140 jobs in a restructuring to save $190 million in the next two years.The job reductions are about 62 percent of Cambridge, Massachusetts-based Aveo’s workforce, the company said today in a statement. Read the full story